Toronto Dominion Bank Has $136.90 Million Holdings in AbbVie Inc. (NYSE:ABBV)

Toronto Dominion Bank boosted its position in AbbVie Inc. (NYSE:ABBV - Free Report) by 10.4% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 770,392 shares of the company's stock after purchasing an additional 72,515 shares during the period. Toronto Dominion Bank's holdings in AbbVie were worth $136,896,000 as of its most recent filing with the SEC.

Several other hedge funds have also bought and sold shares of the company. Sentinus LLC lifted its stake in AbbVie by 1.5% in the 4th quarter. Sentinus LLC now owns 15,788 shares of the company's stock valued at $2,805,000 after purchasing an additional 239 shares during the last quarter. Siemens Fonds Invest GmbH lifted its stake in AbbVie by 197.6% in the 4th quarter. Siemens Fonds Invest GmbH now owns 179,440 shares of the company's stock valued at $32,000 after purchasing an additional 119,141 shares during the last quarter. Security National Bank of SO Dak lifted its stake in AbbVie by 4.9% in the 4th quarter. Security National Bank of SO Dak now owns 17,012 shares of the company's stock valued at $3,023,000 after purchasing an additional 795 shares during the last quarter. SGL Investment Advisors Inc. acquired a new stake in AbbVie in the 4th quarter valued at about $243,000. Finally, Shell Asset Management Co. raised its holdings in AbbVie by 0.5% in the 4th quarter. Shell Asset Management Co. now owns 36,710 shares of the company's stock valued at $6,523,000 after acquiring an additional 167 shares during the period. 70.23% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the stock. Erste Group Bank raised shares of AbbVie to a "strong-buy" rating in a report on Monday, March 17th. BNP Paribas raised shares of AbbVie to a "hold" rating in a report on Thursday, May 8th. The Goldman Sachs Group reissued a "neutral" rating and issued a $194.00 price target on shares of AbbVie in a report on Tuesday, April 8th. Morgan Stanley increased their price target on shares of AbbVie from $241.00 to $250.00 and gave the company an "overweight" rating in a report on Monday, April 28th. Finally, Raymond James reissued an "outperform" rating and issued a $220.00 price target (up from $218.00) on shares of AbbVie in a report on Monday, February 3rd. Eight investment analysts have rated the stock with a hold rating, seventeen have issued a buy rating and four have given a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $210.95.

AbbVie Price Performance

NYSE:ABBV traded up $1.62 during mid-day trading on Monday, reaching $185.64. The stock had a trading volume of 5,210,314 shares, compared to its average volume of 6,243,744. The stock has a 50-day simple moving average of $191.30 and a two-hundred day simple moving average of $186.85. The stock has a market capitalization of $327.92 billion, a PE ratio of 77.35, a P/E/G ratio of 1.62 and a beta of 0.56. The company has a debt-to-equity ratio of 17.94, a current ratio of 0.66 and a quick ratio of 0.55. AbbVie Inc. has a 12 month low of $153.58 and a 12 month high of $218.66.

AbbVie (NYSE:ABBV - Get Free Report) last announced its quarterly earnings data on Friday, April 25th. The company reported $2.46 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.40 by $0.06. The business had revenue of $13.34 billion for the quarter, compared to analysts' expectations of $12.91 billion. AbbVie had a net margin of 7.59% and a return on equity of 296.28%. The firm's quarterly revenue was up 8.4% compared to the same quarter last year. During the same period last year, the firm posted $2.31 earnings per share. On average, equities analysts anticipate that AbbVie Inc. will post 12.31 earnings per share for the current year.

Insider Buying and Selling at AbbVie

In other AbbVie news, EVP Perry C. Siatis sold 5,778 shares of the firm's stock in a transaction that occurred on Thursday, February 20th. The shares were sold at an average price of $197.90, for a total value of $1,143,466.20. Following the sale, the executive vice president now owns 22,381 shares in the company, valued at $4,429,199.90. This trade represents a 20.52% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, SVP Kevin K. Buckbee sold 18,944 shares of the firm's stock in a transaction that occurred on Wednesday, February 26th. The shares were sold at an average price of $203.41, for a total transaction of $3,853,399.04. Following the completion of the sale, the senior vice president now owns 11,496 shares in the company, valued at $2,338,401.36. This represents a 62.23% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 113,471 shares of company stock worth $23,426,451 over the last quarter. Corporate insiders own 0.25% of the company's stock.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.